MX-1 Xenograft Model Service for Breast Cancer

The MX-1 xenograft model provides an exceptionally sensitive in vivo translational platform specifically optimized for validating candidate chemotherapies, PARP inhibitors, and novel targeting strategies against DNA-repair-deficient triple-negative breast cancer (TNBC). Alfa Cytology delivers a comprehensive, end-to-end MX-1 xenograft model service, combining fully authenticated cell line resources with standardized inoculation and evaluation protocols to accelerate preclinical oncology pipelines.

Overview of MX-1 Xenograft Model for Breast Cancer

The MX-1 model is a prominent and highly specialized human mammary carcinoma platform extensively utilized in preclinical oncology to study triple-negative breast cancer (TNBC) biology and therapeutic responsiveness. Originally derived from a surgical biopsy of a primary tumor in a 29-year-old female patient, this model is molecularly categorized by the complete absence of ER, PR, and HER2 receptors. Crucially, MX-1 harbors a distinct genetic hallmark characterized by defective DNA double-strand break repair pathways, frequently associated with a regulatory deficiency or mutation in the BRCA1/2 genomic axes.

When established in vivo as a xenograft in immunodeficient mice, MX-1 develops into hyper-aggressive, poorly differentiated epithelial solid tumors that precisely preserve the hyper-sensitive DNA-damage response and high proliferative index seen in clinical scenarios. Unlike many slow-growing luminal platforms, MX-1 exhibits exceptionally robust tumor take rates, uniform growth kinetics, and rapid in vivo expansion without necessitating exogenous hormonal or supplementation matrices.

Fig 1. YHP-836 enhanced the cytotoxicity of TMZ, TPT, CDDP, and ADM in MX-1 cells. (Du T, et al., 2022)

Cell Line Information: MX-1

The MX-1 cell line maintains a stable epithelial morphology in vitro and reliably preserves its primary receptor-negative status and high chemotherapeutic sensitivity signatures upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MX-1 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including DNA-damage biomarker profiling and PK/PD assessments. Leveraging our expertise in DNA-repair-deficient triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MX-1 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MX-1 xenograft model:

• Cell Culture & Quality Control: MX-1 cells are cultivated in cell-bank-certified growth media under optimized environmental parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Selection & Acclimatization: Standardized immunocompromised mice are selected based on specific study designs and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability MX-1 cells is prepared and blended with a verified biological matrix carrier to optimize spatial distribution and enhance initial cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic mammary fat pad routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. MX-1 Xenograft Model Construction Workflow

Case Study - MX-1 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MX-1 xenograft model was successfully utilized to evaluate the therapeutic efficacy and dosing schedule of a novel targeted PARP inhibitor in combination with a low-dose platinum agent. Under optimized modeling conditions and standardized inoculation protocols, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic synergy.

Our Advantages

Choosing the right partner for your aggressive, DNA-repair-deficient triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks and confirmed sensitivity profiles.
• Technical Consistency: Optimized inoculation protocols ensuring uniform tumor growth and minimizing variance across study cohorts.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, DNA-damage biomarker profiling, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, DNA-repair-deficient triple-negative breast cancer using the robust MX-1 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.